TSHA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TS

Mkt Cap

$1.18B

Volume

2.08M

Next Earnings

November 3rd

Loading chart

TS

TSHATaysha Gene Therapies, Inc. Common Stock

TSHA

Pay with—

Available Balance0.00

TS

Mkt Cap

$1.22B

Volume

2.08M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies granted five new employees 314,000 RSUs and options to purchase 92,400 shares as inducement for employment. The RSUs vest over four years, while stock options have a $5.70 exercise price and 10-year term with four-year vesting schedule.GlobeNewswire Inc. · Sep 4, 2026

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsTaysha Gene Therapies priced an underwritten public offering of 32.5 million shares at $6.00 per share and pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The offering is expected to close on June 26, 2026. The company is a clinical-stage biotech focused on AAV-based gene therapies for CNS diseases, with its lead program TSHA-102 in development for Rett syndrome.GlobeNewswire Inc. · Jun 25, 2026

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6Taysha Gene Therapies announced it will report Q1 2026 financial results and host a conference call on May 6, 2026. The clinical-stage biotech company is advancing AAV-based gene therapies for severe CNS monogenic diseases, with its lead program TSHA-102 in development for Rett syndrome.GlobeNewswire Inc. · Apr 29, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies announced that on April 1, 2026, its Compensation Committee granted four new employees a total of 300,000 restricted stock units and options to purchase 92,400 shares at an exercise price of $4.31. The grants were made under the company's 2023 Inducement Plan as part of their employment agreements.GlobeNewswire Inc. · Apr 3, 2026

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate UpdateTaysha Gene Therapies reported full-year 2025 net loss of $109.0 million and announced significant progress in its lead program TSHA-102 for Rett syndrome treatment. The company has dosed multiple patients in its REVEAL pivotal trial and received FDA clearance for the ASPIRE trial in younger patients (ages 2-4). TSHA-102 maintained a favorable safety profile with no treatment-related serious adverse events. The company expects to complete dosing in both trials by Q2 2026 and has secured FDA alignment on manufacturing and regulatory strategy for its planned BLA submission. Cash position stands at $319.8 million, sufficient to fund operations into 2028.GlobeNewswire Inc. · Mar 19, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies announced that its Compensation Committee granted 349,000 restricted stock units to three new employees on February 2, 2026, as an inducement for employment. The RSUs will vest in four equal annual installments over four years, subject to continued service with the company.GlobeNewswire Inc. · Feb 6, 2026

Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.GlobeNewswire Inc. · Oct 17, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies granted five new employees options to purchase 225,000 shares of common stock under their 2023 Inducement Plan, with options vesting over four years at an exercise price of $2.84.GlobeNewswire Inc. · Sep 5, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Taysha Gene Therapies granted a new employee an option to purchase 90,000 shares of common stock under their 2023 Inducement Plan, with an exercise price of $2.63 and a 10-year term vesting over four years.GlobeNewswire Inc. · Aug 1, 2025

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical ProgramTaysha Gene Therapies announced details for three oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting, covering updates on its TSHA-102 clinical program for Rett syndrome and a symposium on natural history data.GlobeNewswire Inc. · Jun 3, 2025

to start trading

TS

TSHATaysha Gene Therapies, Inc. Common Stock

TSHA

Pay with—

Available Balance0.00

Your PositionYou don't own any TSHA yet.

Related Tickers

Earnings